Transgenic therapeutics to fit your needs
Genovac is the leader in the use of transgenic animal platforms for the generation of fully human, monoclonal antibodies and can assist you in accelerating the development of therapeutic antibodies. The company offers several options for your projects.
OmniAb™ Antibody Discovery
Genovac combines its Antibody Technology with Ligand’s OmniAb™ transgenic rodents for superior human antibody development.
Human Antibodies from Genovac and Ligand Pharmaceutical: Partnering for best-in-class discovery and development services
Combining Genovac Antibody Technology with Ligand’s OmniAb™ transgenic rodents provides clients with accelerated discovery, in vivo optimization for therapeutic efficacy and manufacturability, and fully human sequences for safety and reduced immunogenicity.
A variety of immunization protocols have been applied successfully with OmniAb animals, including DNA, peptide, protein, or cell immunization.The technology also has been used to complete multiple projects with OmniRat™, OmniFlic™ and OmniMouse™ antibody platforms.
By establishing a collaborative workflow between the end user, Ligand and the breeding facility, Genovac can take a project from a target sequence to immunization, fusion, screening and delivery of the desired antibody.
OmniAb Strains vs. Target Classes
OmniRats Kappa & Lambda: Ligand-Receptor Protein Complex
OmniRats Kappa & Lambda: GPCR
Hybridoma and/or B cells are delivered for every antibody project. We also provide the following complementary services:
- Antibody sequencing
- Recombinant antibody production
- Antibody purification from hybridomas
Complete our online form for a complimentary antibody target analysis.
antibody target analysis